Endpoints News

Exclusive: A former AstraZeneca R&I SVP is joining Ailux as CSO, as the Shanghai-based AI biotech eyes its first IND filings in 2027 and prepares to launch its first external fundraise. endpoints.news/china-based-ai…

Roche is expanding its partnership with C4 Therapeutics into degrader-antibody conjugates, putting $20M upfront while DACs emerge as the next frontier in cancer drug design. endpoints.news/roche-dips-int…

Avalyn Pharma is filing for an IPO to fund late-stage work on inhaled pulmonary fibrosis drugs, though investors face at least a year's wait for key clinical data. endpoints.news/pulmonary-fibr…

Gilead doubles down on its push beyond HIV. endpoints.news/gilead-takes-a…

PhRMA chief Steve Ubl is stepping down, sources say. endpoints.news/phrma-head-ste…

Sidewinder raises $137M to advance its bispecific ADC pipeline. endpoints.news/adc-biotech-si…

European VC Jeito closes $1.2B fund to back private biotechs. endpoints.news/european-vc-je…

🚨 PhRMA's CEO @steveubl is stepping down, in a major change atop the powerful drug lobbying group. Endpoints exclusive:

Eli Lilly's $6.3B buy of Centessa lands it a pipeline of orexin drugs — but Wall Street is already wondering if narcolepsy is just the beginning. endpoints.news/did-eli-lilly-…

ARPA-H is backing three academic teams with up to $100M to run clinical trials on experimental joint regeneration therapies for osteoarthritis, with studies expected to begin within 18 months. endpoints.news/arpa-h-selects…

Every blockbuster drug starts with hundreds of hours in the lab. On April 15, join Endpoints for a day exploring how drugs get made — from CRISPR alternatives to AI-driven science to the blood-brain barrier. Free virtual sessions available live and on-demand. Join us. events.endpoints.news/drugday26/1106…

Merck lowered its offer for Terns by $1B after seeing updated clinical data that rattled at least one other would-be buyer enough to walk away entirely. endpoints.news/terns-sold-to-…

Sanofi's bispecific nanobody lunsekimig posted mixed Phase 2 results — passing in asthma and sinusitis, but missing in eczema. endpoints.news/sanofi-bispeci…

Gilead is paying $3.15B upfront to acquire German ADC startup Tubulis, marking its third deal of 2026. endpoints.news/gilead-continu…

Anthropic makes its first $400M biotech bet; Praxis's epilepsy drug hits in early-stage data. endpoints.news/anthropic-pays…

Takeda cuts its last ties with Denali as it trims its pipeline. endpoints.news/takeda-ends-pa…

Stipple Bio debuts with $100M, targeting harder-to-reach sites on cancer proteins. endpoints.news/stipple-bio-la…

Neurocrine pays $2.9B for Soleno, gaining a foothold in Prader-Willi syndrome. endpoints.news/neurocrine-pay…

Exclusive: OpenLoop has acquired Season Health endpoints.news/openloop-healt…

Momentum may be shifting in pharma’s favor on 340B, as the federal government backs drugmakers in key cases challenging state discount laws. endpoints.news/doj-weighs-in-…